Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gesticare DHA is an oral prenatal multivitamin, mineral, iron, and omega‑3 fatty acid (docosahexaenoic acid, DHA) supplement formulated to support increased nutritional needs before, during, and after pregnancy, including prevention of maternal deficiencies and reduction of fetal neural tube defect risk through folic acid provision.[6][10] It typically contains a fixed combination of vitamins (including folic acid), minerals such as iron and calcium, and DHA, which serve as essential cofactors in metabolic pathways, erythropoiesis, bone health, and fetal neural and visual development rather than acting via a single discrete pharmacologic target.[6][10] The product is marketed as a prescription prenatal supplement rather than a therapeutic drug and is used as adjunctive nutritional support in pregnant and lactating women.[6][10]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gesticare DHA.